Search Results - "McSweeney, Peter"

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study by Wang, Michael, Munoz, Javier, Goy, Andre, Locke, Frederick L, Jacobson, Caron A, Hill, Brian T, Timmerman, John M, Holmes, Houston, Jaglowski, Samantha, Flinn, Ian W, McSweeney, Peter A, Miklos, David B, Pagel, John M, Kersten, Marie José, Bouabdallah, Krimo, Khanal, Rashmi, Topp, Max S, Houot, Roch, Beitinjaneh, Amer, Peng, Weimin, Fang, Xiang, Shen, Rhine R, Siddiqi, Rubina, Kloos, Ioana, Reagan, Patrick M

“…Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory…”
Get full text

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial by Locke, Frederick L, Ghobadi, Armin, Jacobson, Caron A, Miklos, David B, Lekakis, Lazaros J, Oluwole, Olalekan O, Lin, Yi, Braunschweig, Ira, Hill, Brian T, Timmerman, John M, Deol, Abhinav, Reagan, Patrick M, Stiff, Patrick, Flinn, Ian W, Farooq, Umar, Goy, Andre, McSweeney, Peter A, Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C, Herrera, Alex F, Bartlett, Nancy L, Wiezorek, Jeffrey S, Navale, Lynn, Xue, Allen, Jiang, Yizhou, Bot, Adrian, Rossi, John M, Kim, Jenny J, Go, William Y, Neelapu, Sattva S

“…Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study,…”
Get full text

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma by Wang, Michael, Munoz, Javier, Goy, Andre, Locke, Frederick L, Jacobson, Caron A, Hill, Brian T, Timmerman, John M, Holmes, Houston, Jaglowski, Samantha, Flinn, Ian W, McSweeney, Peter A, Miklos, David B, Pagel, John M, Kersten, Marie-Jose, Milpied, Noel, Fung, Henry, Topp, Max S, Houot, Roch, Beitinjaneh, Amer, Peng, Weimin, Zheng, Lianqing, Rossi, John M, Jain, Rajul K, Rao, Arati V, Reagan, Patrick M

“…Patients with mantle-cell lymphoma who have a relapse after chemotherapy and anti-CD20 and BTK inhibitor therapy have a poor prognosis. An injection of…”
Get full text

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma by Neelapu, Sattva S., Jacobson, Caron A., Ghobadi, Armin, Miklos, David B., Lekakis, Lazaros J., Oluwole, Olalekan O., Lin, Yi, Braunschweig, Ira, Hill, Brian T., Timmerman, John M., Deol, Abhinav, Reagan, Patrick M., Stiff, Patrick, Flinn, Ian W., Farooq, Umar, Goy, Andre H., McSweeney, Peter A., Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C., Herrera, Alex F., Bartlett, Nancy L., Bot, Adrian A., Shen, Rhine R., Dong, Jinghui, Singh, Kanwarjit, Miao, Harry, Kim, Jenny J., Zheng, Yan, Locke, Frederick L.

“…•Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL.•Durable responses were associated with…”
Get full text

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma by Oluwole, Olalekan O., Bouabdallah, Krimo, Muñoz, Javier, De Guibert, Sophie, Vose, Julie M., Bartlett, Nancy L., Lin, Yi, Deol, Abhinav, McSweeney, Peter A., Goy, Andre H., Kersten, Marie José, Jacobson, Caron A., Farooq, Umar, Minnema, Monique C., Thieblemont, Catherine, Timmerman, John M., Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Kim, Jenny J., Bashir, Zahid, McLeroy, Jeff, Zheng, Yan, Rossi, John M., Johnson, Lisa, Goyal, Lovely, Meerten, Tom

“…Summary ZUMA‐1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi‐cel), an autologous CD19‐directed chimaeric antigen receptor…”
Get full text

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies by Sorror, Mohamed L, Sandmaier, Brenda M, Storer, Barry E, Franke, Georg N, Laport, Ginna G, Chauncey, Thomas R, Agura, Edward, Maziarz, Richard T, Langston, Amelia, Hari, Parameswaran, Pulsipher, Michael A, Bethge, Wolfgang, Sahebi, Firoozeh, Bruno, Benedetto, Maris, Michael B, Yeager, Andrew, Petersen, Finn Bo, Vindeløv, Lars, McSweeney, Peter A, Hübel, Kai, Mielcarek, Marco, Georges, George E, Niederwieser, Dietger, Blume, Karl G, Maloney, David G, Storb, Rainer

“…CONTEXT A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced…”
Get full text

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation by Storb, Rainer, Gyurkocza, Boglarka, Storer, Barry E, Sorror, Mohamed L, Blume, Karl, Niederwieser, Dietger, Chauncey, Thomas R, Pulsipher, Michael A, Petersen, Finn B, Sahebi, Firoozeh, Agura, Edward D, Hari, Parameswaran, Bruno, Benedetto, McSweeney, Peter A, Maris, Michael B, Maziarz, Richard T, Langston, Amelia A, Bethge, Wolfgang, Vindeløv, Lars, Franke, Georg-Nikolaus, Laport, Ginna G, Yeager, Andrew M, Hübel, Kai, Deeg, H Joachim, Georges, George E, Flowers, Mary E D, Martin, Paul J, Mielcarek, Marco, Woolfrey, Ann E, Maloney, David G, Sandmaier, Brenda M

“…We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies…”
Get full text

Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation by Sorror, Mohamed, Storer, Barry, Sandmaier, Brenda M., Maloney, David G., Chauncey, Thomas R., Langston, Amelia, Maziarz, Richard T., Pulsipher, Michael, McSweeney, Peter A., Storb, Rainer

“…BACKGROUND Elderly and medically infirm cancer patients are increasingly offered allogeneic nonmyeloablative hematopoietic cell transplantation (HCT). A better…”
Get full text

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning by SORROR, Mohamed L, STORER, Barry E, WADE, James C, BRUNO, Benedetto, LANGSTON, Amelia, RADICH, Jerald, NIEDERWIESER, Dietger, BLUME, Karl G, STORB, Rainer, MALONEY, David G, SANDMAIER, Brenda M, MARIS, Michael, SHIZURU, Judith, MAZIARZ, Richard, AGURA, Edward, CHAUNCEY, Thomas R, PULSIPHER, Michael A, MCSWEENEY, Peter A

“…We reported encouraging early results of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had…”
Get full text

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma by Maffini, Enrico, Storer, Barry E, Sandmaier, Brenda M, Bruno, Benedetto, Sahebi, Firoozeh, Shizuru, Judith A, Chauncey, Thomas R, Hari, Parameswaran, Lange, Thoralf, Pulsipher, Michael A, McSweeney, Peter A, Holmberg, Leona, Becker, Pamela S, Green, Damian J, Mielcarek, Marco, Maloney, David G, Storb, Rainer

“…We previously reported initial results in 102 multiple myeloma (MM) patients treated with sequential high-dose melphalan and autologous hematopoietic cell…”
Get full text

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study by Nash, Richard A., McSweeney, Peter A., Crofford, Leslie J., Abidi, Muneer, Chen, Chien-Shing, Godwin, J. David, Gooley, Theodore A., Holmberg, Leona, Henstorf, Gretchen, LeMaistre, C. Fred, Mayes, Maureen D., McDonagh, Kevin T., McLaughlin, Bernadette, Molitor, Jerry A., Nelson, J. Lee, Shulman, Howard, Storb, Rainer, Viganego, Federico, Wener, Mark H., Seibold, James R., Sullivan, Keith M., Furst, Daniel E.

“…More effective therapeutic strategies are required for patients with poor-prognosis systemic sclerosis (SSc). A phase 2 single-arm study of high-dose…”
Get full text

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience by Shadman, Mazyar, Maloney, David G., Storer, Barry, Sandmaier, Brenda M., Chauncey, Thomas R., Smedegaard Andersen, Niels, Niederwieser, Dietger, Shizuru, Judith, Bruno, Benedetto, Pulsipher, Michael A., Maziarz, Richard T., Agura, Edward D., Hari, Parameswaran, Langston, Amelia A., Maris, Michael B., McSweeney, Peter A., Storb, Rainer, Sorror, Mohamed L.

“…Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II…”
Get full text

Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy by Deeg, H. Joachim, O'Donnell, Margaret, Tolar, Jakub, Agarwal, Rajni, Harris, Richard E., Feig, Stephen A., Territo, Mary C., Collins, Robert H., McSweeney, Peter A., Copelan, Edward A., Khan, Shakila P., Woolfrey, Ann, Storer, Barry

“…In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI)…”
Get full text

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning by Kahl, Christoph, Storer, Barry E., Sandmaier, Brenda M., Mielcarek, Marco, Maris, Michael B., Blume, Karl G., Niederwieser, Dietger, Chauncey, Thomas R., Forman, Stephen J., Agura, Edward, Leis, Jose F., Bruno, Benedetto, Langston, Amelia, Pulsipher, Michael A., McSweeney, Peter A., Wade, James C., Epner, Elliot, Bo Petersen, Finn, Bethge, Wolfgang A., Maloney, David G., Storb, Rainer

“…Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignancies depends on graft-versus-tumor effects for…”
Get full text

Relationship of Reconstituted Adaptive and Innate Cytomegalovirus (CMV)-Specific Immune Responses with CMV Viremia in Hematopoietic Stem Cell Transplant Recipients by Barron, Michelle A., Gao, Dexiang, Springer, Kathryn L., Patterson, Julie A., Brunvand, Mark W, McSweeney, Peter A., Chang, Zeng, Barón, Anna E., Weinberg, Adriana

“…Background. Cytomegalovirus (CMV) is a major cause of morbidity in transplant recipients. An immunologic predictor of protection against CMV reactivation or…”
Get full text

Remission of severe myasthenia gravis after autologous stem cell transplantation by Schlatter, Monica I, Yandamuri, Soumya S, O'Connor, Kevin C, Nowak, Richard J, Pham, Minh C, Obaid, Abeer H, Redman, Callee, Provost, Marie, McSweeney, Peter A, Pearlman, Michael L, Tees, Michael T, Bowen, James D, Nash, Richard A, Georges, George E

“…Myasthenia gravis (MG) is an autoantibody-mediated neuromuscular junction disorder involving the acetylcholine receptors on the motor endplate. The safety and…”
Get full text

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors by HEGENBART, Ute, NIEDERWIESER, Dietger, AL-ALI, Haifa, STORER, Barry, MALONEY, David, MCSWEENEY, Peter, CHAUNCEY, Thomas, AGURA, Ed, BRUNO, Benedetto, MAZIARZ, Richard T, PETERSEN, Finn, STORB, Rainer, SANDMAIER, Brenda M, MARIS, Michael B, SHIZURU, Judith A, GREINIX, Hildegard, CORDONNIER, Catherine, RIO, Bernard, GRATWOHL, Alois, LANGE, Thoralf

“…The use of low-dose, irradiation-based preparative regimens have allowed the extension of allografting to older and medically infirm patients. The study…”
Get full text

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases by Niederwieser, Dietger, Maris, Michael, Shizuru, Judith A., Petersdorf, Effie, Hegenbart, Ute, Sandmaier, Brenda M., Maloney, David G., Storer, Barry, Lange, Thoralf, Chauncey, Thomas, Deininger, Michael, Pönisch, Wolfram, Anasetti, Claudio, Woolfrey, Ann, Little, Marie-Terese, Blume, Karl G., McSweeney, Peter A., Storb, Rainer F.

“…Toxicities of high-dose conditioning regimens have limited the use of conventional unrelated donor hematopoietic cell transplantation (HCT) to younger,…”
Get full text

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting by Rotta, Marcello, Storer, Barry E., Sahebi, Firoozeh, Shizuru, Judith A., Bruno, Benedetto, Lange, Thoralf, Agura, Edward D., McSweeney, Peter A., Pulsipher, Michael A., Hari, Parameswaran, Maziarz, Richard T., Chauncey, Thomas R., Appelbaum, Frederick R., Sorror, Mohamed L., Bensinger, William, Sandmaier, Brenda M., Storb, Rainer F., Maloney, David G.

“…Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cytoreduction and graft-versus-myeloma…”
Get full text

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects by McSweeney, Peter A., Niederwieser, Dietger, Shizuru, Judith A., Sandmaier, Brenda M., Molina, Arthur J., Maloney, David G., Chauncey, Thomas R., Gooley, Theodore A., Hegenbart, Ute, Nash, Richard A., Radich, Jerald, Wagner, John L., Minor, Steven, Appelbaum, Frederick R., Bensinger, William I., Bryant, Eileen, Flowers, Mary E.D., Georges, George E., Grumet, F. Carl, Kiem, Hans-Peter, Torok-Storb, Beverly, Yu, Cong, Blume, Karl G., Storb, Rainer F.

“…Toxicities have limited the use of allogeneic hematopoietic cell transplantation (HCT) to younger, medically fit patients. In a canine HCT model, a combination…”
Get full text